China Resources 39: Promoting The Inheritance And Innovation Of Traditional Chinese Medicine And Giving Full Play To The Responsibilities And Responsibilities Of Central Enterprises

2021 is the first year of the 14th five year plan, and also the historical intersection of realizing the two centenary goals. It is of great significance to the majority of pharmaceutical enterprises, which are the main force to realize the strategic goal of "healthy China".

Recently, on the occasion of the 100th anniversary of the founding of the Communist Party of China, Qiu Huawei, Secretary of the Party committee and President of China Resources 39th, gave an exclusive exposition to the 21st century economic report on how China Resources 39 plays a central role in promoting the inheritance and innovation of traditional Chinese medicine, and how to match the "14th five year plan" plan, national grand strategies such as healthy China and powerful science and technology to drive the development of enterprises.

China Resources Sanjiu Pharmaceutical Co., Ltd. is a large state-owned listed pharmaceutical company, mainly engaged in the R & D, production, sales and related health services of pharmaceutical products.

The predecessor of the company is Shenzhen Nanfang pharmaceutical factory, which was established in 1985. In 1999, five companies, including Sanjiu enterprise group and Shenzhen Sanjiu Pharmaceutical Co., Ltd., initiated the establishment of joint-stock companies; On March 9, 2000, it was listed on Shenzhen Stock Exchange (Stock Code: 000999); In 2008, it officially entered China Resources Group; In 2010, the name of the company was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.".

The core business of China Resources 39 is positioned in the fields of CHC health consumer goods and Rx prescription drugs. Its business covers nearly 10 categories, such as cold, skin, gastrointestinal, cough, orthopedics, pediatrics, etc. in addition, it has continued to lay out in the core fields of digestion, cardio cerebral diseases and cancer, ranking the forefront in the domestic market.

At present, China Resources 39 has 21 varieties with annual sales of over 100 million yuan“ "999" brand enjoys high recognition in consumers and pharmaceutical industry. 999 Ganmaoling granules / capsules have won the first place in cold and cough category (Chinese patent medicine) for many years.

The core business of runsanjiu is positioned in the fields of CHC health consumer goods and Rx prescription drugs. Visual China

Strengthening the leading role of Party building in scientific research

21st century: as a large state-owned listed pharmaceutical company, how does China Resources 39 play the advanced role of Party organizations and Party members in the construction and management?

Qiu Huawei: Party organizations and Party members are not only the bridge and link between the party and the grassroots people, but also the backbone force for the development of social economy and the promotion of all-round social progress.

As a state-owned enterprise with red gene, China Resources Sanjiu has always attached great importance to the important role of grass-roots party organizations and Party members in the construction and management of enterprises in accordance with the requirements of comprehensively and strictly administering the party. It has made great efforts to strengthen the construction of grass-roots party organizations and Party members, and give full play to the role of grassroots party organizations as a fighting fortress and the vanguard and exemplary role of Party members and cadres, Lead all staff to innovate continuously and create good economic benefits.

We should integrate party building into all aspects of production and operation, and give full play to the advanced nature of Party organizations and Party members in daily enterprise management and specific production affairs.

In the company's innovation and development, strengthen scientific research. China Resources has strengthened the leadership of Party building, built "branches in the company", set up a technical research team for Party members, and gave full play to the role of the party organization as a fighting fortress and the vanguard and exemplary role of Party members.

Taking the research of traditional Chinese medicine as an example, "development of traditional Chinese medicine" has become a national strategy.

Members of the Party group of the national pharmaceutical center of the company overcome difficulties, study the production information management technology with the production and manufacturing execution as the core, establish the informatization and process management system of Chinese patent medicine production, study and apply advanced systems and intelligent equipment to the production process, and build an intelligent management and control system integrating production, management, service and other manufacturing activities.

In order to overcome the problems such as insufficient thymus resources and wild chrysanthemum resources protection, the company established a key problem solving team for medicinal materials resources. The backbone members of the team were not afraid of difficulties and dangers. For many years, they took the lead to go deep into Zhanjiang, Yunfu, Guangzhou, Huangshi and other bases, successfully solved the problems of industrialized supply of thymus seeds and wild chrysanthemum medicinal materials, and ensured the stable supply of core medicinal materials of the company, It also provides a path for the development and protection of wild medicinal materials.

In terms of epidemic prevention and anti epidemic work. After the outbreak of the epidemic, China Resources Sanjiu bravely took on the responsibility of state-owned enterprises, rapidly made overall arrangements for all production enterprises, gave full play to the unique role and value of traditional Chinese medicine in the actual anti epidemic war, and gave priority to the production of "Shenfu Injection", "Shengmai Injection" and several preventive and therapeutic prescriptions of traditional Chinese medicine formula granules, so as to supply the epidemic areas with the fastest speed.

During this period, more than 10 "party members' commandos" were set up by various party organizations of the company to do a good job in product quality inspection, complete emergency production tasks, transport materials day and night, and donate anti epidemic supplies, and inject red power into winning the war with practical actions.

In the fight against the epidemic last year, on January 24, 2020 (New Year's Eve), the national pharmaceutical business department set up the "new crown pneumonia prevention team" to lead the division's marketing, production, supply chain, functions and other cross departmental personnel, a total of 35 people, to form the mainstay of the internal fight against pneumonia, give full play to the vanguard and exemplary role of Party members, take the initiative to work overtime, prepare, adjust, rush production, and As of March 10, 2020, a total of 45200 boxes of formula granule drugs were sold to all parts of the country, with a value of about 200 million yuan. They sent medical support to the front line of fighting the epidemic and contributed "three nine strength".

21st century: how does China Resources 39 match the national strategies of the 14th five year plan, healthy China, and powerful science and technology to drive the development of enterprises?

Qiu Huawei: the company conscientiously implements the 14th five year plan and the outline of the long-term goal in 2035. Guided by the national development strategy of the 14th five year plan, the company integrates "health", "innovation" and "reform" into the "13th five year" strategic plan of China Resources, focusing on innovative research and development of high-quality medical and health products and intelligent manufacturing, so as to promote high-quality development, Committed to become the first brand of Chinese medicine and health.

Focusing on strategic areas, adhering to the concept of strengthening the country through science and technology, the company continues to increase R & D investment and accelerate the construction of innovation system. The "Guangdong Lingnan medicine resources and modern Chinese medicine intelligent manufacturing innovation center" jointly declared by China Resources Sanjiu was approved for construction in 2020. In the aspect of inheritance and innovation of traditional Chinese medicine, the company focuses on the research of classic prescriptions, formula granule standards and medicinal materials resources, continuously increases investment, and actively explores the road of inheritance and development of traditional Chinese medicine.

In terms of regional strategy, China Resources 39 takes the domestic big cycle as the main body, combines with the national regional development strategy, completes the development and deployment work of key regions in the "14th five year plan", and implements one zone and one policy according to the division of "4 + 1 + n" regions of China Resources Group. In Guangdong, Hong Kong and Macao Bay area, give full play to the advantages of the headquarters, focus on innovation, and promote the high-quality development of the company.

The revitalization of traditional Chinese medicine will enter a golden period of rapid development

21st century: what impetus do you think the advent of Internet medicine will bring to the prescription drug industry and self diagnosis and treatment?

Qiu Huawei: since 2020, the development environment of internet medical industry has been continuously improved, and various factors have promoted the internet medical industry to enter a period of rapid development.

In terms of policy, the policy restrictions on the internet medical industry are gradually relaxed, and a number of supportive policies have been issued intensively.

In November 2020, the measures for the supervision and administration of online drug sales (Draft for comments) officially pointed out the direction of online sales of prescription drugs, allowing online sales of prescription drugs and display of prescription drug information.

In April 2021, the opinions on some special measures to support the construction of Hainan free trade port and relax market access put forward: support the development of Internet prescription drug sales. Hainan e-prescription center will be established in the free trade zone. All prescription drugs (except for special management drugs) listed in the domestic market are allowed to be sold on the Internet through the electronic prescription center, and the unified collection of prescription information, purchase of prescription drugs, medical insurance settlement and other matters can be realized through "one network".

Secondly, in the environment of epidemic prevention and control, users have gradually cultivated the habit of asking for medical advice and buying drugs on the line. The increase of online medical popularization rate has accelerated the development of the industry and the number of users has increased rapidly.

The development of Internet medicine will promote the outflow of prescriptions, and more drug sales will flow from the hospital to the outside market. According to the data of meinei.com, the proportion of retail drug sales in the total drug sales of the three terminals (public hospital, primary medical care and retail pharmacy) has been increasing, from 22.5% in 2016 to 23.4% in 2019.

The online penetration rate of retail terminal continues to increase, and online sales increase rapidly. In the two modes of online and physical retail drugstores, the growth rate of online pharmacies is much higher than that of physical pharmacies. The sales volume of online pharmacies will be 13.8 billion yuan in 2019, with a year-on-year increase of 39.4%; The sales volume of physical pharmacies was 405.7 billion yuan, with a year-on-year increase of only 6.2%. Online pharmacies have strong growth momentum.

"21st century": the state has issued a series of policies to encourage and support the development of traditional Chinese medicine industry. With the continuous refinement and improvement of various policies, what major opportunities do you think the inheritance and innovation of traditional Chinese medicine are facing? How to look at the optimization structure of Chinese medicine industry in the future?

Qiu Huawei: "during the 13th Five Year Plan period, the revitalization and development of traditional Chinese medicine was mentioned at the national strategic level, and was positioned as" playing a leading role in the prevention of disease, playing a synergistic role in the treatment of major diseases, and playing a core role in the rehabilitation of diseases "“ During the period of the 14th five year plan, the inheritance and innovation policies of traditional Chinese medicine were refined, the investment and construction efforts were increased, the favorable policies were expected to be gradually realized, and the revitalization of traditional Chinese medicine was about to enter a golden period of rapid development.

In terms of optimizing the management of review and approval of traditional Chinese medicine, it is proposed to "accelerate the reform of the review and approval mechanism of traditional Chinese medicine, establish an effective mechanism for new Chinese medicine to enter the rapid review and approval channel" and "increase the number of third-party registration and inspection institutions of new Chinese medicine"; In terms of improving the management of classification and registration of traditional Chinese medicine, it is proposed to "optimize the review and approval of new Chinese medicine with human experience", "establish the evidence system of traditional Chinese medicine registration and review of" Three Combinations "of TCM theory, human experience and clinical trials, and establish the evidence system of real world research of traditional Chinese medicine".

During the "14th five year plan" period, the state will also implement the "major project for the revitalization and development of traditional Chinese medicine". It includes two parts: one is the major project of traditional Chinese medicine focusing on capital construction. It mainly includes national Chinese medicine center, regional Chinese medicine medical center, national traditional Chinese Medicine Inheritance and innovation center, national traditional Chinese medicine disease prevention and control base, and "flagship" Hospital of Chinese and Western medicine cooperation.

Second, major projects of traditional Chinese medicine focusing on capacity improvement. It mainly includes the basic level TCM service ability improvement project, TCM advantage specialty, TCM pre treatment service ability, TCM rehabilitation service ability improvement, etc.

During the period of the 14th five year plan, it is expected that the central government's investment in major projects will double that of the 13th Five Year Plan period. At present, the traditional Chinese medicine industry is in the stage from extensive growth to high-quality development, there are still a series of problems, such as uneven quality of Chinese medicine resources, low concentration of Chinese medicine industry, weak basic research, lack of evidence-based evidence, etc.

In terms of optimizing the industrial structure, as a central enterprise, CR-39, as a central enterprise, should play its role in promoting the inheritance and innovation of traditional Chinese medicine, and shoulder the responsibility of promoting the upgrading and development of traditional Chinese medicine industry.

First of all, we should start from ourselves, standardize the standards, and formulate the standards of each link from the upstream drug breeding to the end market decocting service, so as to lay a solid foundation for the development of the entire industrial chain from the source.

Secondly, it is necessary to improve the management ability of the industrial chain. On the basis of the establishment of the standards, we should take the whole process traceability as the starting point, collect and manage the information of each link of the industrial chain, so as to escort the intelligent and high-quality development of the whole industrial chain.

Third, promote innovation. We should continue to increase innovation, attach importance to scientific research, and make up for the shortcomings of the industry in terms of technology.

Fourth, focus on integrated development. Explore cross industry integration development, including cooperation between enterprises, government and public medical institutions, and enhance industrial value. China Resources 39 will take practical actions to promote the continuous upgrading and high-quality development of the Chinese medicine industry.

?